Dupilumab is a human monoclonal antibody of isotype IgG4 that targets the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. Dupilumab inhibits the signaling pathway of interleukins, that induce inflammatory and immunological reactions in several atopic or allergic conditions, such as eczema, allergic reaction, and rhinosinusitis.Dupilumab has been marketed under the trade name Dupixent. It has been also investigated for the treatment of diseases driven by allergic reactions or type 2 inflammation, such as pediatric atopic dermatitis, eosinophilic esophagitis, and chronic obstructive pulmonary disease.
There are no reviews yet.
Your email address will not be published. Required fields are marked *
In which application did you use the antibody? *
Did it work in your application? *
Your review *
Save my name, email, and website in this browser for the next time I comment.
Got a question or need a quote? Message us and we’ll get back to you 48 hours or less.
Lab / Company